2-((2'-(5-ethyl-3-(4-fluorophenyl)-4-phenyl-1H-pyrazol-1-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid

ID: ALA5285216

Max Phase: Preclinical

Molecular Formula: C31H25FN2O3

Molecular Weight: 492.55

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CCc1c(-c2ccccc2)c(-c2ccc(F)cc2)nn1-c1ccccc1-c1cccc(OCC(=O)O)c1

Standard InChI: InChI=1S/C31H25FN2O3/c1-2-27-30(21-9-4-3-5-10-21)31(22-15-17-24(32)18-16-22)33-34(27)28-14-7-6-13-26(28)23-11-8-12-25(19-23)37-20-29(35)36/h3-19H,2,20H2,1H3,(H,35,36)

Standard InChI Key: MHPVCNCCDDESOD-UHFFFAOYSA-N

Molfile:

 
     RDKit          2D

 37 41  0  0  0  0  0  0  0  0999 V2000
   -3.5319   -2.4767    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8174   -2.8892    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8174   -3.7142    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1029   -2.4767    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1029   -1.6516    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3884   -1.2391    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3884   -0.4138    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6782   -0.0019    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0381   -0.4101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0381   -1.2387    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6764   -1.6510    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7527   -1.6512    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4702   -1.2369    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1839   -1.6496    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1839   -2.4722    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4692   -2.8849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7527   -2.4758    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4702   -0.4119    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1375    0.0729    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9345   -0.1406    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5179    0.4427    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8826    0.8574    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2952    1.5720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1238    1.5720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5319    2.2884    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1201    2.9986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2948    2.9986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8828    2.2866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0577    0.8574    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6453    1.5720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0596    2.2895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6431    2.9996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1777    2.9996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5904    2.2849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1797    1.5720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5903    3.7142    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.8028    0.0729    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  2  3  1  0
  4  2  1  0
  5  4  1  0
  6  5  1  0
  7  6  2  0
  8  7  1  0
  9  8  2  0
 10  9  1  0
 11 10  2  0
  6 11  1  0
 12 10  1  0
 13 12  1  0
 14 13  2  0
 15 14  1  0
 16 15  2  0
 17 16  1  0
 12 17  2  0
 18 13  1  0
 19 18  1  0
 19 20  1  0
 20 21  1  0
 22 19  2  0
 22 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 23  2  0
 29 22  1  0
 29 30  1  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 33 34  2  0
 34 35  1  0
 35 30  2  0
 33 36  1  0
 37 29  2  0
 18 37  1  0
M  END

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type:	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 492.55	Molecular Weight (Monoisotopic): 492.1849	AlogP: 7.04	#Rotatable Bonds: 8
Polar Surface Area: 64.35	Molecular Species: ACID	HBA: 4	HBD: 1
#RO5 Violations: 1	HBA (Lipinski): 5	HBD (Lipinski): 1	#RO5 Violations (Lipinski): 1
CX Acidic pKa: 3.83	CX Basic pKa: 1.72	CX LogP: 7.57	CX LogD: 4.32
Aromatic Rings: 5	Heavy Atoms: 37	QED Weighted: 0.25	Np Likeness Score: -0.87

References

1. Floresta G, Pistarà V, Amata E, Dichiara M, Marrazzo A, Prezzavento O, Rescifina A.. (2017) Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review., 138 [PMID:28738306] [10.1016/j.ejmech.2017.07.022]
2. Lehmann, Fredik F and 8 more authors. 2004-09-06 Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. [PMID:15357969]
3. Barf, Tjeerd T and 9 more authors. 2009-03-15 N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors. [PMID:19217286]
4. Hertzel, Ann V AV and 9 more authors. 2009-10-08 Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins. [PMID:19754198]
5. Cai, Haiyan H and 5 more authors. 2010-06-15 Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening. [PMID:20471252]
6. Liu, Xiujie X and 10 more authors. 2011-05-15 New aromatic substituted pyrazoles as selective inhibitors of human adipocyte fatty acid-binding protein. [PMID:21481589]
7. Zhou, Yang Y and 8 more authors. 2016-09-15 The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation. [PMID:27460668]
8. Kühne, Holger H and 13 more authors. 2016-10-15 Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors. [PMID:27658368]
9. Gao, Ding-Ding DD and 12 more authors. 2018-06-25 From hit to lead: Structure-based discovery of naphthalene-1-sulfonamide derivatives as potent and selective inhibitors of fatty acid binding protein 4. [PMID:29775936]
10. Oukoloff, Killian; Lucero, Bobby; Francisco, Karol R; Brunden, Kurt R and Ballatore, Carlo. 2019-03-01 1,2,4-Triazolo[1,5-a]pyrimidines in drug design. [PMID:30703745]

2-((2'-(5-ethyl-3-(4-fluorophenyl)-4-phenyl-1H-pyrazol-1-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Calculated Properties

References

Source